To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy. Background: In the era of effective chemotherapy for colorectal liver metastases, the association between surgical margin status and survival has become controversial. Methods: Clinicopathologic data and outcomes for 378 patients treated with modern preoperative chemotherapy and hepatectomy were analyzed. The effect of positive margins on OS was analyzed in relation to pathologic and computed tomography-based morphologic response to chemotherapy. Results: Fifty-two of 378 resections (14%) were R1 resections (tumor-free margin <1 mm). The 5-year OS rates for patients with R0 resection (margin ≥1 mm) and R1 resection were 55% and 26%, respectively (P = 0.017). Multivariate analysis identified R1 resection (P = 0.03) and a minor pathologic response to chemotherapy (P = 0.002) as the 2 factors independently associated with worse survival. The survival benefit associated with negative margins (R0 vs R1 resection) was greater in patients with suboptimal morphologic response (5-year OS rate: 62% vs 11%; P = 0.007) than in patients with optimal response (3-year OS rate: 92% vs 88%; P = 0.917) and greater in patients with a minor pathologic response (5-year OS rate: 46% vs 0%; P = 0.002) than in patients with a major response (5-year OS rate: 63% vs 67%; P = 0.587).
in operative techniques and strategies (ie, portal vein embolization and staged hepatectomy), and surgical selection criteria based less on conventional clinicopathologic factors and more on the ability to clear disease while leaving behind an adequate future liver remnant, have contributed to an increasing number of patients being offered resection with curative intent. [3] [4] [5] Importantly, these advances have been paralleled by the development of highly effective chemotherapeutic and biologic agents for patients with metastatic colorectal cancer. [6] [7] [8] [9] [10] Contemporary systemic therapy for patients with CLMs typically includes either oxaliplatin-or irinotecan-containing regimens, often combined with targeted agents such as bevacizumab or cetuximab. Preoperative administration of such systemic therapy in patients with CLMs has been shown to result in high response rates and increased rates of resectability. [7] [8] [9] Recent investigations have also demonstrated that response to preoperative chemotherapy as assessed by histologic evaluation of the surgical specimen after resection of CLMs is a valuable predictor of survival in patients with CLMs. 11, 12 In addition, we recently found that chemotherapy-induced morphologic changes detected on preoperative computed tomography (CT) correlated with both pathologic response and survival and seemed to represent a useful clinical surrogate for disease biology. 13, 14 Traditionally, one of the criteria used to select patients for hepatectomy for CLMs has been the predicted ability to achieve pathologically negative surgical margins. This paradigm is supported by several studies demonstrating that the so-called R1 resection (tumorfree margin <1 mm) is associated with worse overall survival (OS) than R0 resection (tumor-free margin ≥1 mm). [15] [16] [17] [18] [19] However, other studies have found that R1 resection does not achieve independent significance as a predictor of survival in multivariate analysis. 16, 20, 21 These include a study published in 2008 that found similar 5-year OS rates after R0 and R1 resection (61% and 57%, respectively) among 436 patients treated with perioperative chemotherapy and an aggressive surgical approach. 20 These conflicting findings regarding the impact of positive margins raise the question of whether R1 resection negatively impacts survival because of the adverse effect of microscopic residual tumor left behind at the time of surgery or rather reflects a more aggressive tumor phenotype that makes complete resection with histologically negative margins harder to achieve. That question is difficult to answer on the basis of results of prior studies, given the heterogeneity of the patients and treatment modalities in those studies.
The objective of this study was to better understand the impact of surgical margin status on OS after surgical resection of CLMs while accounting for tumor biology as assessed by response to preoperative chemotherapy. To do this, we analyzed a homogeneous group
METHODS Patient Inclusion Criteria
The prospectively maintained hepatobiliary surgical database at The University of Texas MD Anderson Cancer Center was queried to identify all consecutive patients with CLMs treated with preoperative chemotherapy and subsequent hepatectomy with curative intent between September 1997 and January 2010. Patients treated with concomitant radiofrequency ablation were excluded. Patients with extrahepatic metastases were also excluded from the study. Clinicopathologic data (described in detail under the "Statistical Analysis" section) were extracted from the patients' medical records. Institutional review board approval was obtained before data retrieval and analysis.
Preoperative Assessment
Preoperative assessment included a medical history, physical examination, laboratory evaluation, and imaging studies. Helical CT with liver protocol or magnetic resonance imaging was used to define the extent and location of CLMs. Beginning in 1998, fluorodeoxyglucose positron emission tomography was selectively used both to rule out extensive extrahepatic disease and to confirm the metastatic nature of atypical lesions. 22 Imaging studies were reviewed by an experienced hepatobiliary radiologist, and our previously described CT-related morphologic criteria were used to assess morphologic response to preoperative chemotherapy. 13, 14 In brief, CLM response was classified in group 3 if there was heterogeneous attenuation and a thick, poorly defined tumor-liver interface; in group 1 if there was homogeneous low attenuation and a thin, sharply defined tumor-liver interface; and in group 2 if there were mixed characteristics. Morphologic response to preoperative chemotherapy was defined as optimal if CLMs changed from group 3 or 2 to group 1. Morphologic response was defined as suboptimal if CLMs changed from group 3 to group 2, remained in the same category, or changed to a higher numbered group. In patients with multiple CLMs, morphologic response was scored on the basis of the response seen in most lesions.
Treatment plans were made during case presentations at a multidisciplinary liver tumor conference attended by hepatobiliary surgeons, diagnostic radiologists, interventional radiologists, and medical oncologists. Decision making was based on the location and extent of CLMs, the presence of extrahepatic disease, and radiographic response to preoperative chemotherapy. Hepatectomy was considered in patients with CT volumetry, indicating that all CLMs could be safely resected with preservation of a sufficient future liver remnant. In patients with an anticipated insufficient future liver remnant volume, preoperative portal vein embolization was used to induce hypertrophy of the future liver remnant. 23
Surgical Procedure
During laparotomy, the peritoneal cavity was inspected to rule out previously unrecognized extrahepatic disease. Intraoperative ultrasonography of the liver was performed in each case both to confirm and to better define the location of CLMs and their relation to portal pedicles and hepatic veins. Parenchymal transection was performed under total or selective hepatic inflow vascular exclusion, using the cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO), and hemostasis was achieved using saline-linked cautery (dissecting sealer DS 3.0; Tissuelink Medical, Inc, Dover, NH). 24 For this study, major hepatectomy was defined as resection of 3 or more contiguous liver segments according to the Couinaud classification. 25 
Postoperative Evaluation
Postoperative mortality was defined as any death within 90 days after resection, and postoperative morbidity was defined as any complication within the same time period. Postoperative complications were graded according to a standard classification system. 26 Major complications were classified as complications requiring surgical, endoscopic, or radiologic intervention (grade III); life-threatening complications requiring intensive care management (grade IV); and death (grade V). Postoperative liver insufficiency was defined as a postoperative peak bilirubin level more than 7 mg/dL. 27 All specimens were subjected to histologic evaluation to confirm the diagnosis of metastatic colorectal cancer, the degree of pathologic response to preoperative chemotherapy, and the width of the tumor cell-free surgical margin. Margin width was determined prospectively using the shortest distance from the edge of the tumor to the line of parenchymal transection. R1 resection was defined as the presence of tumor cells within the space up to 1 mm from the transection line, whereas R0 resection was defined as complete tumor resection with no tumor cells within 1 mm of the transection line. 16 Pathologic response to preoperative chemotherapy was graded as previously described, 12 with the area of residual viable tumor cells within each metastatic lesion estimated as a percentage of the total tumor surface area. CLMs with 0% to 49% residual viable tumor cells were considered to have a major pathologic response, whereas CLMs with 50% or more residual viable tumor cells were considered to have a minor pathologic response. In patients with multiple tumor nodules, the mean of the values for the various nodules was used to define overall pathologic response.
Statistical Analysis
Quantitative and qualitative variables were summarized in terms of median (range), mean (standard deviation), and frequency (percentage). Comparisons between groups were analyzed with the χ 2 or Fisher exact test for categorical variables and the Mann-Whitney U test for continuous variables, as appropriate. Patients were stratified by pathologic response to preoperative chemotherapy, and the clinicopathologic characteristics of patients who had a major pathologic response were compared with the clinicopathologic characteristics of patients who had a minor response. OS rates were calculated from the date of resection to the date of death or last follow-up, using the Kaplan-Meier method and compared using log-rank tests. The effect of R1 resection on OS was analyzed both in the entire patient cohort and in subgroups of patients stratified by pathologic and morphologic responses to preoperative chemotherapy.
To identify risk factors associated with OS in groups of patients treated with preoperative chemotherapy and subsequent hepatectomy for CLMs, we evaluated the following clinicopathologic variables in univariate analysis: sex (male vs female), age (≥60 years vs <60 years), body mass index (>30 kg/m 2 vs ≤30 kg/m 2 ), timing of detection of CLMs (synchronous vs metachronous), location of the primary tumor (rectum vs colon), status of the regional lymph nodes for the primary tumor (positive vs negative), preoperative chemotherapy for CLMs (irinotecan vs oxaliplatin), preoperative systemic therapy with bevacizumab (administered vs not), preoperative systemic therapy with cetuximab (administered vs not), number of cycles of preoperative chemotherapy (≥6 vs <6), pathologic response to preoperative chemotherapy (major vs minor), 2-stage hepatectomy (performed vs not), portal vein embolization (performed vs not), associated procedure (performed vs not), major hepatectomy (performed vs not), major postoperative complication (yes vs no), blood transfusion required (yes vs no), estimated blood loss (>1000 mL vs ≤1000 mL), number of CLMs (multiple vs solitary), diameter of the largest of the CLMs (≥3 cm vs <3 cm), carcinoembryonic antigen level (≥10 ng/mL vs <10 ng/mL), status of the resection margins on microscopic analysis (R1 vs R0), and postoperative chemotherapy for CLMs (administered vs not).
All variables associated with survival with P ≤ 0.1 in the univariate proportional hazards models were subsequently entered into a Cox multivariate regression model with backward elimination. P ≤ 0.05 values were considered statistically significant. Statistical analyses were performed using the SPSS software package, version 19.2 (SPSS, Chicago, IL).
RESULTS

Patient Characteristics
Among 494 consecutive patients who underwent hepatectomy for CLMs after preoperative chemotherapy during the study period, 116 patients were treated with concomitant radiofrequency ablation and were excluded from the study. Clinicopathologic data of the remaining 378 patients are summarized in Table 1 . The median age was 58 years (range, 25-85 years), and 56% of the patients were men. The median number of CLMs was 2 (range, 1-75), and 49% of patients had CLMs with the largest diameter 3 cm or more. Preoperative chemotherapy regimens included oxaliplatin in 62% of patients and irinotecan in 38% of patients, and the median number of cycles was 6 (range, 2-36). Bevacizumab and cetuximab were used in combination with chemotherapy in 61% and 6% of the patients, re-spectively. Postoperative chemotherapy was offered to medically fit patients with the intention of completing a combined preoperative plus postoperative total of 6 months of systemic treatment. A total of 217 patients (57%) had a major pathologic response to preoperative chemotherapy, whereas 161 patients (43%) had a minor pathologic response.
The majority of the patients (259/378, 69%) underwent major hepatectomy, including 104 patients (28%) who underwent extended hepatectomy. Thirty patients (8%) underwent staged hepatectomy, consisting of a limited resection of CLMs located in the left liver, followed by right (with or without segment 4) portal vein embolization and subsequent right (or extended right) hepatectomy, to achieve complete tumor resection. At histologic evaluation, 52 patients (14%) had R1 resection whereas 326 patients (86%) had R0 resection. Postoperative chemotherapy for CLMs was administered to 260 patients (69%), including 71% of patients with a minor pathologic response to preoperative therapy and 67% with a major pathologic response. In patients with a minor pathologic response to preoperative chemotherapy, the postoperative chemotherapy regimen was either enriched with bevacizumab or cetuximab (depending on prior exposure and k-ras mutation status) or the entire regimen was changed to a second line of modern chemotherapy.
Morphologic response to preoperative chemotherapy was evaluable for 202 of the 378 patients studied. In the remaining 176 patients, morphologic response could not be assessed because of a small tumor size, lack of high-quality prechemotherapy CT imaging, or the use of magnetic resonance imaging as the preoperative imaging modality. Sixty-five patients (32%) had an optimal morphologic response, and 137 patients (68%) had a suboptimal morphologic response.
Patient Characteristics by Response to Preoperative Chemotherapy
Patient characteristics by pathologic response to preoperative chemotherapy (major or minor) are summarized in Table 1 . Synchronous presentation of CLMs was more frequent in patients with a major pathologic response (70%) than in patients with a minor response (59%) (P = 0.033). The median diameter of the largest of the CLMs was larger in patients with a minor pathologic response [3 (range, 1-18) cm] than in patients with a major response [2 (1-16) cm] (P < 0.0001). Although within the normal range, the median preoperative carcinoembryonic antigen level was higher in patients with a minor pathologic response [5 (range, 1-1392) ng/mL] than in patients with a major response [2 (range, 0-727) ng/mL] (P < 0.0001). Fewer patients with a major pathologic response than patients with a minor response required perioperative blood transfusion (14% vs 23%) (P = 0.030). Finally, positive surgical margins were more common in patients with minor response than in patients with major response (18% vs 11%; P = 0.033). There was no association between the number of CLMs and the response to preoperative chemotherapy (P = 0.592) or between necessity for major hepatectomy and the response to preoperative chemotherapy (P = 0.944).
When analyzing the association between morphologic response and pathologic response to preoperative chemotherapy, a close correlation between these factors was observed. In patients with type 1 response, type 2 response, and type 3 morphologic response, the proportion of patients with a minor pathologic response was 7%, 13%, and 81%, respectively. Surgical margin status, however, was not associated with the type of morphologic response to preoperative chemotherapy (P = 0.333).
Postoperative Mortality and Morbidity
The postoperative 90-day mortality rate was 3% (11 patients died). Three deaths were related to postoperative liver insufficiency in patients who underwent extended hepatectomy after prolonged preoperative chemotherapy (>6 cycles). Four deaths were related to pulmonary or intra-abdominal infections, and 4 patients died of thromboembolic complications (myocardial infarction or pulmonary embolism). The postoperative 90-day morbidity rate was 28% (107/378 patients). Perioperative complications recorded using a standard grading system included 32 grade I, 12 grade II, 37 grade III, 15 grade IV, and 11 grade V complications. 26 Sixteen percent of study patients experienced a major complication necessitating operative, endoscopic, or radiologic intervention.
Long-Term Survival
At a median follow-up time of 32 months (range, 1-118 months), the median survival for the entire cohort (N = 378) was 62 months. The 3-, 5-, and 10-year OS rates were 70%, 53%, and 21%, respectively. Patients who underwent R0 resection (n = 326) had a significantly better 5-year OS rate than those who underwent R1 resection (n = 52) (55% vs 26%; P = 0.017) (Fig. 1) .
The effect of surgical margin status on OS was analyzed in relation to morphologic tumor response to preoperative chemotherapy. Among the 65 patients with an optimal morphologic response, there was no difference in 3-year OS rates between patients with R0 and R1 resection (92% and 88%, respectively; P = 0.917) (Fig. 2) . In contrast, among the 137 patients with a suboptimal morphologic tumor response, the 5-year OS rate was significantly better after R0 resection (62% vs 11%; P = 0.007) ( Fig. 3) .
Likewise, in patients with a major pathologic response to preoperative chemotherapy, the 5-year OS rates were similar after R0 and R1 resection (63% and 67%, respectively; P = 0.587) ( Fig. 4) . However, in patients with a minor pathologic response to preoperative chemotherapy, the 5-year OS rate was significantly better after R0 resection (46% vs 0%; P = 0.002) ( Fig. 5) . 95% confidence interval (CI), 1.27-2.86; P = 0.002] and R1 resection (HR, 1.69; 95% CI, 1.05-2.74; P = 0.03) were independently associated with OS ( Table 2) .
In patients with a major pathologic response to preoperative chemotherapy (Table 3 ), univariate analysis demonstrated that predictors of worse OS were primary rectal carcinoma (P = 0.035), regional lymph node metastases of the primary tumor (P = 0.036), and major postoperative complication (P = 0.005). On multivariate analysis, only major postoperative complication (HR, 2.40; 95% CI, 1.21-4.76; P = 0.012) remained as a significant predictor of survival (Table 3) .
In patients with a minor pathologic response to preoperative chemotherapy (Table 4 ), univariate analysis demonstrated that predictors of worse OS were multiple CLMs (P = 0.014), diameter of the largest CLM 3 cm or more (P = 0.039), and R1 resection (P = 0.002). On multivariate analysis, R1 resection (HR, 2.04; 95% CI, 1.15-3.60; P = 0.014) was the only factor found to predict worse OS.
DISCUSSION
The gold standard for the surgical management of CLMs is complete resection with histologically negative margins. 28 The current study confirms the importance of achieving R0 resection in a homogeneous population treated with resection with curative intent after delivery of modern systemic chemotherapy consisting of oxaliplatinor irinotecan-based regimens. Survival analysis of the entire patient cohort revealed a 5-year OS rate of 55% after R0 resection compared with 26% after R1 resection. These survival rates are similar to those reported in previous studies analyzing the impact of surgical margin status on the outcome of patients with CLMs. 16, 21, 29 These results are in contrast to the recently published study by de Haas et al, 20 in which no difference in OS was identified between patients with R0 resection and patients with R1 resection. Of note, however, only 73% of patients in that study were treated with preoperative systemic therapy and only 49% received contemporary chemotherapy regimens containing oxaliplatin or irinotecan. These differences in the delivery and composition of preoperative chemotherapy may explain the findings of each study.
In the current study, the magnitude of benefit associated with a negative margin was strongly influenced by the pathologic response to preoperative chemotherapy. For patients with a major pathologic response (0%-49% residual viable tumor cells), surgical margin status did not impact survival: the 5-year OS rate was 63% after R0 resection and 67% after R1 resection. However, for patients with a minor pathologic response to preoperative chemotherapy (≥50% residual viable tumor cells), the 5-year OS rate was 46% after R0 resection and 0% after R1 resection, although equivalent proportions of patients in the 2 groups received additional postoperative systemic therapy. In addition, multivariate analysis identified R1 margin as the only independent risk factor for poor survival in patients with a minor pathologic response to preoperative chemotherapy. These data indicate that postoperative systemic therapy cannot rescue patients from a combination of chemotherapy resistance and positive surgical margins and emphasize the dominant impact of tumor biology on outcomes.
Although pathologic response to preoperative chemotherapy was found to be a powerful predictor of long-term outcomes, it is obviously not available at the time of selection of patients for surgical resection of CLMs. Given the frequent use of preoperative chemotherapy in patients with CLMs, 30 a noninvasive method for evaluating tumor response to cytotoxic chemotherapy and predicting long-term outcomes would facilitate informed consent, risk stratification, and the proper timing and sequence of tumor-directed therapy. In this regard, our group has published CT-based morphologic criteria that accurately predicted pathologic response to preoperative chemotherapy and correlated with OS in patients with CLMs treated surgically and nonsurgically. 13 The analysis of CT morphologic criteria in this study is concordant with our previous results, further supporting its reliability as a predictor of pathologic response.
Although we would not suggest that clearly resectable patients be denied surgical therapy on the basis of morphologic response to preoperative chemotherapy, the study supports the value of morphologic (CT-based) response in selecting patients with extensive disease for resection of CLMs. For patients with an optimal morphologic response, no survival difference was observed between patients who underwent R0 and those who underwent R1 resection (3-year OS rates were 92% and 88%, respectively), indicating that operative therapy should proceed in this group even when close margins are anticipated by proximity of tumors to vascular structures. However, for patients with a suboptimal morphologic response, the 5-year OS rate was 62% after R0 resection compared with only 11% after R1 resection, suggesting that patients in this group anticipated to have close margins may be better served with second-line systemic therapies. Thus, the influence of surgical margin status in relation to CT-based morphologic response to chemotherapy mirrors the influence of surgical margin status in relation to pathologic response identified in surgical specimens. For a variety of malignancies, response to chemotherapy is known to be a sensitive marker for tumor biology and is recognized as an important prognostic indicator. [31] [32] [33] [34] Previous data from our institution 12 and others 11 have demonstrated that degree of tumor cell killing in response to preoperative chemotherapy is a significant predictor of survival after hepatectomy for CLMs. Similarly, in the current study, minor pathologic response was found to be an independent predictor of worse survival on multivariate analysis of the entire cohort. In light of these findings and the 5-year survival rate of 0% in patients with a minor pathologic response to preoperative chemotherapy and R1 resection, aggressive surgical therapy should be pursued in patients with unfavorable tumor biology (as indicated by a suboptimal morphologic response to preoperative chemotherapy) only when a negative margin is clearly achievable. In contrast, in patients with an optimal morphologic response to preoperative chemotherapy, aggressive surgical therapy may be appropriate even if there is some concern that R0 resection may not be achievable.
This study may be limited by its retrospective nature. It may also be limited by inclusion of patients treated with 2 different chemotherapy regimens, although the regimens were contemporary (oxaliplatin-and irinotecan-based). Another potential limitation is that biologic agents that have been demonstrated to contribute to the effectiveness of cytotoxic therapy (ie, bevacizumab) 6, 35 were not used in all cases. Despite these potential limitations, this represents the first study to examine the impact of surgical margin status in a homogeneous patient population treated with modern cytotoxic chemotherapy. Another possible limitation of this study is that morphologic response to preoperative therapy could not be evaluated in all patients because criteria for morphologic response are currently CTbased and some patients had undergone magnetic resonance imaging or had tumors too small to permit an accurate qualitative assessment of response. This represents the third study to confirm the association between morphologic response to preoperative therapy, pathologic response to preoperative therapy, and long-term outcomes. 13, 14 In the future we plan to further investigate these associations and to validate the morphologic response criteria, using alternative imaging modalities including magnetic resonance imaging.
In most studies on CLMs, prognostic factors associated with survival after resection of CLMs have included number, size, and distribution of hepatic lesions, the disease status of the primary tumor lymph nodes, the disease-free interval before detection of CLMs, and the preoperative carcinoembryonic antigen level. 29, 36 These prognostic factors are recorded either at initial presentation or before resection but are unrelated to preoperative treatment and variably reflect tumor biology. In this context, the predicted likelihood of achieving a microscopically negative surgical margin has always been a concern but has continued to be a point of controversy. 20 The current study, performed on a homogeneous cohort of patients who received preoperative chemotherapy with modern agents, serves to resolve some of this controversy. The findings indicate that patients with CLMs and suboptimal response to preoperative chemotherapy are unlikely to benefit from surgery unless all tumors can be resected with microscopically negative margins.
CONCLUSIONS
In conclusion, this analysis supports a continued emphasis on achieving R0 resection in patients with CLMs. The use of modern chemotherapy combined with aggressive surgical strategies has expanded the number of patients considered for resection of CLMs and has resulted in improved long-term OS. For patients who demonstrate unfavorable tumor biology, as assessed by both traditional clinicopathologic criteria and more recently introduced imaging criteria, an aggressive surgical approach should be entertained only if R0 resection is deemed feasible.
